- South Africa
- Hong Kong
- New Zealand
- Czech Republic
- United Kingdom
President and General Manager, Emerging Markets and Established Products
Led by David Simmons, Pfizer's Established Products Business Unit (EPBU) was created in 2008 to provide patients with lower-cost medicines characterized by Pfizer's reputation for quality, safety and innovation. Much of the business unit's success is due to its entrepreneurial culture characterized by a "fast, flexible, focused and accountable" pursuit of profitable growth opportunities.
Established products are medicines that have lost or are close to losing their exclusivity. Pfizer has a portfolio of over 600 established products - including many familiar brands such as Norvasc, Zoloft, and Zithromax. Established products include solid oral dose medications, sterile injectables and orphan therapeutic products.
Under Simmons' leadership, EPBU broke new ground for the company by in-licensing more than 200 molecules from partner companies. EPBU is uniquely positioned to help Pfizer meet its commitment to set the standard for quality, safety and value of medicines. In an industry that too often suffers from quality and supply issues, Pfizer's strong reputation for product integrity and reliability sets it apart from the competition. Since its inception, the EPBU has shared a unique relationship with the Emerging Markets Business Unit (EMBU).
The EMBU consists of 19,000 colleagues in over 70 countries across 20 time zones — all with unique cultures, languages, tremendous skills and talents. The EMBU strives to meet the diverse medical needs of more than 5.5 billion patients in emerging markets around the world in an innovative, socially responsible and commercially viable manner. Since 2009, the business unit has launched innovative ways of doing business adapted to the unique needs of local markets in Latin America, Africa, the Middle East and emerging markets in Asia and Europe.
Innovative models include partnerships (such as with the Clinton Foundation and Grameen Health) to increase access to Pfizer medicines and services.
In his new role as the President and General Manager of Emerging Markets and Established Products Business Units, Simmons will lead colleagues from around the globe on a strategic mission that emphasizes driving access to high quality, affordable medicines; pursuing strategic acquisitions and partnerships; and seeking game-changing opportunities — enabled by a commitment to operational excellence, integrity, communication and a winning entrepreneurial culture.
David Simmons brings 14 years of international Pfizer experience — including executive responsibilities in the United Kingdom, Greece, Canada and the United States — and nine years of experience in the steel industry to his role as President and General Manager of the Emerging Markets and Established Products Business Units. He serves as the Executive Sponsor of the Pfizer African American Leadership Network, and as a member of the U.S.-India Business Council.